Extended Follow-up of Microbiome Therapeutic SER-109 Through 24 Weeks for Recurrent Clostridioides difficile Infection in a Randomized Clinical Trial.

Authors

Stuart H Cohen
Thomas J Louie
Matthew Sims, Beaumont Health
Elaine E L Wang
Asli Memisoglu
Barbara H McGovern
Lisa von Moltke

Document Type

Article

Publication Date

11-22-2022

Publication Title

JAMA

Abstract

This study examines adverse events and durability of response of SER-109, an investigational microbiome therapeutic comprised of purified Firmicutes spores, compared with placebo for Clostridioides difficile infection.

Volume

328

Issue

20

First Page

2062

Last Page

2064

Recommended Citation

Cohen SH, Louie TJ, Sims M, Wang EEL, Memisoglu A, McGovern BH, et al. Extended follow-up of microbiome therapeutic SER-109 through 24 weeks for recurrent Clostridioides difficile infection in a randomized clinical trial. JAMA. 2022 Nov 22;328(20):2062-2064. doi: 10.1001/jama.2022.16476. PMID: 36260754.

DOI

10.1001/jama.2022.16476

ISSN

1538-3598

PubMed ID

36260754